CervoMed Inc.
(CRVO)
undefined
undefined%
At close: undefined
Company Description
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases.
It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery.
The company is based in Boston, Massachusetts.
CervoMed Inc.
| Country | United States |
| IPO Date | May 23, 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Dr. John J. Alam M.D. |
Contact Details
Address: 20 Park Plaza Boston, Massachusetts United States | |
| Website | https://www.cervomed.com |
Stock Details
| Ticker Symbol | CRVO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001053691 |
| CUSIP Number | n/a |
| ISIN Number | US15713L1098 |
| Employer ID | 30-0645032 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. John J. Alam M.D. | Co-Founder, Chief Executive Officer, President & Director |
| Dr. Robert J. Cobuzzi Jr., Ph.D. | Chief Operating Officer & Director |
| William Robert Elder J.D. | Chief Financial Officer & General Counsel |
| Dr. Claudia Ordonez M.D. | Senior Vice President of Medical Science |
| Dr. Mark A. De Rosch Ph.D. | SVice President of Regulatory & Government Affairs & Program Management |
| Dr. Sylvie L. Gregoire Pharm.D. | Co-Founder & Director |
| Kelly Blackburn M.H.A. | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 10, 2024 | 8-K | Current Report |
| Dec 03, 2024 | 8-K | Current Report |
| Nov 27, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 04, 2024 | 8-K | Current Report |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 16, 2024 | 8-K | Current Report |
| Oct 11, 2024 | 424B3 | Filing |